Effect of Metamorphed Keratolytic Agent on the Behavior of Imiquimod Loaded Hybrid Vesicles Containing Gel.
The cost, side effects, and patient compliance-related issues of topically effective imiquimod have prevented its widespread acceptance. The present work intends to evaluate the feasibility of overcoming the shortcomings of poorly soluble and skin-penetrating immunomodulator by using biocompatible keratolytic agent with drug-loaded hybrid vesicles. Salicylic acid was complexed with phospholipid through simple mixing and incorporated into carbopol 940 gel containing drug-loaded vesicles, prepared by thin-film hydration method. The morphology, physicochemical properties, rheological behavior, release profile, and dermatokinetics of developed gel were compared with control gel (developed gel without keratolytic agent). In ex vivo drug release studies across the rat skin, there was significant increase in the steady-state permeation flux (Jss) and skin retention of drug from developed gel in comparison with control. There was favorable change in almost every evaluated dermatokinetic parameter. The innocuous nature of control gel had not changed on addition of skin structure-altering agent. The developed gel was found to be stable at room temperature and humidity for 1 year.
['Sharma|Mandeep|M|', 'Sharma|Gajanand|G|', 'Raza|Kaisar|K|', 'Singh|Bhupinder|B|', 'Katare|Om Prakash|OP|']
D000287:Administration, Topical D000818:Animals D003879:Dermatologic Agents D004337:Drug Carriers D016503:Drug Delivery Systems D005260:Female D005782:Gels D000077271:Imiquimod D007641:Keratolytic Agents D008297:Male D051379:Mice D010316:Particle Size D010539:Permeability D010743:Phospholipids D051381:Rats D017207:Rats, Sprague-Dawley D020156:Salicylic Acid D012867:Skin D012869:Skin Absorption
biocompatibility complexation phospholipid skin drug delivery system hydrogel immune response liposomes pharmacokinetics toxicity